Cargando…

Low Complement C4 Predicts Improvement of Kidney Function After Direct‐Acting Antiviral Therapy for Hepatitis C Virus

Direct‐acting antiviral therapies (DAAs) may improve kidney function and proteinuria in certain patients with hepatitis C infection (HCV) and chronic kidney disease (CKD). To improve our understanding of HCV‐mediated kidney dysfunction, we aimed to evaluate the baseline predictors of improvement in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sise, Meghan E., Strohbehn, Ian, Chute, Donald, Corey, Kathleen E., Fusco, Dahlene N., Sabbisetti, Venkata S, Waikar, Sushrut S., Chung, Raymond T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395066/ https://www.ncbi.nlm.nih.gov/pubmed/32766479 http://dx.doi.org/10.1002/hep4.1528

Ejemplares similares

Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection
por: Lin, Ming V., et al.
Publicado: (2016)

Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C–Viremic Donor to Uninfected Recipient Kidney Transplantation
por: Sise, Meghan E., et al.
Publicado: (2020)

Lupus-Like Immune Complex-Mediated Glomerulonephritis in Patients With Hepatitis C Virus Infection Treated With Oral, Interferon-Free, Direct-Acting Antiviral Therapy
por: Sise, Meghan E., et al.
Publicado: (2016)

Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma
por: Seethapathy, Harish, et al.
Publicado: (2020)

Plasma Kidney Injury Molecule-1 in Systemic Lupus Erythematosus: Discordance Between ELISA and Proximity Extension Assay
por: Schmidt, Insa M., et al.
Publicado: (2022)

Physician Attitudes on Kidney Biopsies for Research: A Survey Study
por: McMahon, Gearoid M., et al.
Publicado: (2019)

COVID-19 Survival and its impact on chronic kidney disease
por: LONG, JOSHUA D., et al.
Publicado: (2022)

Safety and Efficacy of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir for Hepatitis C Virus Infection Across All Levels of Kidney Function
por: Sise, Meghan E.
Publicado: (2018)

The Associations of Plasma Biomarkers of Inflammation With Histopathologic Lesions, Kidney Disease Progression, and Mortality—The Boston Kidney Biopsy Cohort Study
por: Srivastava, Anand, et al.
Publicado: (2021)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Medication-related adverse events in patients with cancer and discrepancies in cystatin C- versus creatinine-based eGFR
por: Hanna, Paul E., et al.
Publicado: (2023)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Acute Kidney Injury Incidence, Recovery, and Long-term Kidney Outcomes Among Hospitalized Patients With COVID-19 and Influenza
por: Strohbehn, Ian A., et al.
Publicado: (2021)

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD
por: Balk, Ethan M., et al.
Publicado: (2022)

Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C
por: Schaefer, Esperance A K, et al.
Publicado: (2016)

Medication-Related Adverse Events and Discordancies in Cystatin C–Based vs Serum Creatinine–Based Estimated Glomerular Filtration Rate in Patients With Cancer
por: Hanna, Paul E., et al.
Publicado: (2023)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19
por: Kumar, Pramod, et al.
Publicado: (2021)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis
por: Zhang, Hang, et al.
Publicado: (2023)

Uric Acid and Acute Kidney Injury in the Critically Ill
por: Srivastava, Anand, et al.
Publicado: (2019)

Hepatitis C Virus-associated Membranoproliferative Glomerulonephritis Treated with Directly Acting Antiviral Therapy
por: Nayak, S., et al.
Publicado: (2018)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

Effect of Cancer Stage on Adverse Kidney Outcomes in Patients Receiving Immune Checkpoint Inhibitors for Melanoma
por: Wang, Qiyu, et al.
Publicado: (2022)

Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
por: Antoniou, Tony, et al.
Publicado: (2023)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct‐acting antivirals
por: Nevola, Riccardo, et al.
Publicado: (2020)

Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
por: Gaglio, Paul J., et al.
Publicado: (2011)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_oti36stbqr1vj3j0g8il5dcn5a